BACKGROUND: Population-based human immunodeficiency virus type 1 (HIV-1) RNA levels (viral load [VL]) are proposed metrics for antiretroviral therapy (ART) program effectiveness. We estimated population-based HIV RNA levels using a fingerprick-based approach in a rural Ugandan community implementing rapid ART scale-up. METHODS: A fingerprick-based HIV RNA measurement technique was validated against standard phlebotomy. This technique was deployed during a 5-day community-wide health campaign in a 6300-person community. Assessments included rapid HIV antibody testing, VL, and CD4+ T-cell count via fingerprick. We estimated population HIV RNA levels and the prevalence of undetectable RNA, assessed predictors of VL via linear regression, and mapped RNA levels within community geographic units. RESULTS: During the community-wide health campaign, 179 of 2282 adults (7.8%) and 10 of 1826 children (0.5%) tested seropositive for HIV. Fingerprick VL was determined in 174 of 189 HIV-positive persons (92%). The mean log(VL) was 3.67 log (95% confidence interval [CI], 3.50-3.83 log copies/mL), median VL was 2720 copies/mL (interquartile range, <486-38 120 copies/mL), and arithmetic mean VL was 64 064 copies/mL. Overall, 64 of 174 of individuals had undetectable RNA (37% [95% CI, 30%-44%]), 24% had VL 486-10 000; 25% had VL 10 001-100 000; and 15% had VL>100 000 copies/mL. Among participants taking ART, 83% had undetectable VL. CONCLUSIONS: We developed and implemented a fingerprick VL testing method and provide the first report of population HIV RNA levels in Africa. In a rural Ugandan community experiencing ART scale-up, we found evidence of population-level ART effectiveness, but found a substantial population to be viremic, in need of ART, and at risk for transmission.
BACKGROUND: Population-based human immunodeficiency virus type 1 (HIV-1) RNA levels (viral load [VL]) are proposed metrics for antiretroviral therapy (ART) program effectiveness. We estimated population-based HIV RNA levels using a fingerprick-based approach in a rural Ugandan community implementing rapid ART scale-up. METHODS: A fingerprick-based HIV RNA measurement technique was validated against standard phlebotomy. This technique was deployed during a 5-day community-wide health campaign in a 6300-person community. Assessments included rapid HIV antibody testing, VL, and CD4+ T-cell count via fingerprick. We estimated population HIV RNA levels and the prevalence of undetectable RNA, assessed predictors of VL via linear regression, and mapped RNA levels within community geographic units. RESULTS: During the community-wide health campaign, 179 of 2282 adults (7.8%) and 10 of 1826 children (0.5%) tested seropositive for HIV. Fingerprick VL was determined in 174 of 189 HIV-positive persons (92%). The mean log(VL) was 3.67 log (95% confidence interval [CI], 3.50-3.83 log copies/mL), median VL was 2720 copies/mL (interquartile range, <486-38 120 copies/mL), and arithmetic mean VL was 64 064 copies/mL. Overall, 64 of 174 of individuals had undetectable RNA (37% [95% CI, 30%-44%]), 24% had VL 486-10 000; 25% had VL 10 001-100 000; and 15% had VL>100 000 copies/mL. Among participants taking ART, 83% had undetectable VL. CONCLUSIONS: We developed and implemented a fingerprick VL testing method and provide the first report of population HIV RNA levels in Africa. In a rural Ugandan community experiencing ART scale-up, we found evidence of population-level ART effectiveness, but found a substantial population to be viremic, in need of ART, and at risk for transmission.
Authors: Gregorio A Millett; Jeffrey S Crowley; Howard Koh; Ronald O Valdiserri; Thomas Frieden; Carl W Dieffenbach; Kevin A Fenton; Regina Benjamin; Jack Whitescarver; Jonathan Mermin; Deborah Parham-Hopson; Anthony S Fauci Journal: J Acquir Immune Defic Syndr Date: 2010-12 Impact factor: 3.731
Authors: Scott J Filler; Andres A Berruti; Nick Menzies; Rick Berzon; Tedd V Ellerbrock; Robert Ferris; John M Blandford Journal: J Acquir Immune Defic Syndr Date: 2011-05-01 Impact factor: 3.731
Authors: Julio S G Montaner; Viviane D Lima; Rolando Barrios; Benita Yip; Evan Wood; Thomas Kerr; Kate Shannon; P Richard Harrigan; Robert S Hogg; Patricia Daly; Perry Kendall Journal: Lancet Date: 2010-07-16 Impact factor: 79.321
Authors: Melanie A Thompson; Judith A Aberg; Pedro Cahn; Julio S G Montaner; Giuliano Rizzardini; Amalio Telenti; José M Gatell; Huldrych F Günthard; Scott M Hammer; Martin S Hirsch; Donna M Jacobsen; Peter Reiss; Douglas D Richman; Paul A Volberding; Patrick Yeni; Robert T Schooley Journal: JAMA Date: 2010-07-21 Impact factor: 56.272
Authors: Moupali Das; Priscilla Lee Chu; Glenn-Milo Santos; Susan Scheer; Eric Vittinghoff; Willi McFarland; Grant N Colfax Journal: PLoS One Date: 2010-06-10 Impact factor: 3.240
Authors: Morna Cornell; Karl Technau; Lara Fairall; Robin Wood; Harry Moultrie; Gilles van Cutsem; Janet Giddy; Lerato Mohapi; Brian Eley; Patrick MacPhail; Hans Prozesky; Helena Rabie; Mary-Ann Davies; Nicola Maxwell; Andrew Boulle Journal: S Afr Med J Date: 2009-09
Authors: Evan Wood; Thomas Kerr; Brandon D L Marshall; Kathy Li; Ruth Zhang; Robert S Hogg; P Richard Harrigan; Julio S G Montaner Journal: BMJ Date: 2009-04-30
Authors: Lisa M Prach; Adrian Puren; Sheri A Lippman; Sergio Carmona; Sophie Stephenson; Ewalde Cutler; Scott Barnhart; Teri Liegler Journal: J Clin Microbiol Date: 2014-12-17 Impact factor: 5.948
Authors: Sunil Suhas Solomon; Shruti H Mehta; Allison M McFall; Aylur K Srikrishnan; Shanmugam Saravanan; Oliver Laeyendecker; Pachamuthu Balakrishnan; David D Celentano; Suniti Solomon; Gregory M Lucas Journal: Lancet HIV Date: 2016-03-11 Impact factor: 12.767
Authors: Michael Mauk; Jinzhao Song; Haim H Bau; Robert Gross; Frederic D Bushman; Ronald G Collman; Changchun Liu Journal: Lab Chip Date: 2017-01-31 Impact factor: 6.799
Authors: Lillian B Brown; Diane V Havlir; James Ayieko; Florence Mwangwa; Asiphas Owaraganise; Dalsone Kwarisiima; Vivek Jain; Theodore Ruel; Tamara Clark; Gabriel Chamie; Elizabeth A Bukusi; Craig R Cohen; Moses R Kamya; Maya L Petersen; Edwin D Charlebois Journal: AIDS Date: 2016-11-28 Impact factor: 4.177
Authors: Changchun Liu; Shih-Chuan Liao; Jinzhao Song; Michael G Mauk; Xuanwen Li; Gaoxiang Wu; Dengteng Ge; Robert M Greenberg; Shu Yang; Haim H Bau Journal: Lab Chip Date: 2016-02-07 Impact factor: 6.799
Authors: Rose Wafula; Sarah Masyuko; Lucy Ng'ang'a; Andrea A Kim; Anthony Gichangi; Irene Mukui; James Batuka; Evelyn W Ngugi; William K Maina; Sandra Schwarcz Journal: J Acquir Immune Defic Syndr Date: 2014-05-01 Impact factor: 3.731
Authors: Vivek Jain; Dathan M Byonanebye; Teri Liegler; Dalsone Kwarisiima; Gabriel Chamie; Jane Kabami; Maya L Petersen; Laura B Balzer; Tamara D Clark; Douglas Black; Harsha Thirumurthy; Elvin H Geng; Edwin D Charlebois; Gideon Amanyire; Moses R Kamya; Diane V Havlir Journal: J Acquir Immune Defic Syndr Date: 2014-03-01 Impact factor: 3.731